These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33073348)

  • 1. B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic - when immunosuppression meets infection?
    Mycko MP
    Neurol Neurochir Pol; 2020; 54(6):490-501. PubMed ID: 33073348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
    Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
    Front Immunol; 2021; 12():796482. PubMed ID: 35111162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
    Margoni M; Preziosa P; Filippi M; Rocca MA
    J Neurol; 2022 Mar; 269(3):1316-1334. PubMed ID: 34382120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
    Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
    Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Navigating the landscape of COVID-19 for Multiple Sclerosis patients and clinicians.
    Dyczkowska K; Kalinowska-Łyszczarz A
    Neurol Neurochir Pol; 2023; 57(1):90-100. PubMed ID: 36727546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
    Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
    Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study.
    Heidler F; Baldt J; Frahm N; Langhorst SE; Mashhadiakbar P; Streckenbach B; Zettl UK; Richter J
    Eur Neurol; 2022; 85(2):104-111. PubMed ID: 34743082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monoclonal antibody therapies for rapidly progressive and highly active multiple sclerosis in the era of the COVID-19 pandemic].
    Eliseeva DD; Vasiliev AV; Abramova AA; Kochergin IA; Zakharova MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7. Vyp. 2):31-36. PubMed ID: 34387443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.
    Azimzadeh M; Möhn N; Ghane Ezabadi S; Moghimi Esfandabadi Z; Soleimani A; Ranjbar E; Jahromi M; Seyedebrahimi R; Skripuletz T; Moharrami Kasmaie F
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
    Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
    Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
    Front Immunol; 2020; 11():1059. PubMed ID: 32477373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.
    Alborghetti M; Bellucci G; Gentile A; Calderoni C; Nicoletti F; Capra R; Salvetti M; Centonze D
    Curr Neuropharmacol; 2022; 20(1):107-125. PubMed ID: 33784961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab.
    Pedotti R; Muros-Le Rouzic E; Raposo C; Schippling S; Jessop N
    Mult Scler Relat Disord; 2021 Oct; 55():103203. PubMed ID: 34411984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study.
    Conte WL
    Mult Scler Relat Disord; 2022 Jan; 57():103413. PubMed ID: 35158480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
    Tazza F; Lapucci C; Cellerino M; Boffa G; Novi G; Poire I; Mancuso E; Bruschi N; Sbragia E; Laroni A; Capello E; Inglese M
    J Neurol Sci; 2021 Aug; 427():117501. PubMed ID: 34044238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
    Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
    Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.